tremelimumab astrazeneca
astrazeneca ab - tremelimumab - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
cozaar filmuhúðuð tafla 50 mg
n.v. organon* - losartanum kalíum - filmuhúðuð tafla - 50 mg
cozaar filmuhúðuð tafla 100 mg
n.v. organon* - losartanum kalíum - filmuhúðuð tafla - 100 mg
presmin filmuhúðuð tafla 50 mg
alvogen ehf. - losartanum kalíum - filmuhúðuð tafla - 50 mg
losartan medical valley filmuhúðuð tafla 12,5 mg
medical valley invest ab - losartanum kalíum - filmuhúðuð tafla - 12,5 mg
prednisolon eql pharma tafla 5 mg
eql pharma ab - prednisolonum inn - tafla - 5 mg
combisyn stungulyf, dreifa 14,0/3,5 % w/v
norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - stungulyf, dreifa - 14,0/3,5 % w/v
cloxacillin vital pharma nordic stungulyfs-/innrennslisstofn, lausn 2 g
vital pharma nordic aps - cloxacillinum natríum - stungulyfs-/innrennslisstofn, lausn - 2 g
doktacillin stungulyfs-/innrennslisstofn, lausn
viatris aps - ampicillinum natríum - stungulyfs-/innrennslisstofn, lausn
ferinject stungulyf/innrennslislyf, ördreifa 50 mg/ml
vifor france - ferricum carboxymaltosum inn - stungulyf/innrennslislyf, ördreifa - 50 mg/ml